Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associated autologous anti-vimentin antibody, CLN-IgG (Pritumumab)

The British Journal of Cancer Research has just released a new paper co-authored by Nascent Biotech founder Dr. Mark C. Glassy entitled, “Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associatedautologous anti-vimentin antibody, CLN-IgG (Pritumumab)”.

Click here to download the paper.

Click here to download the supplementary information.

The Economist: Closing In On Cancer

The Economist has published a fascinating overview of cancer research’s progress, including immunotherapy:

The greatest excitement is reserved for immunotherapy, a new approach that has emerged in the past few years. The human immune system is equipped with a set of brakes that cancer cells are able to activate; the first immunotherapy treatment in effect disables the brakes, enabling white blood cells to attack the tumours. It is early days, but in a small subset of patients this mechanism has produced long-term remissions that are tantamount to cures. Well over 1,000 clinical trials of such treatments are under way, targeting a wide range of different cancers. It is even now possible to reprogram immune cells to fight cancer better by editing their genomes; the first such gene therapy was approved for use in America last month.

Click here to read the complete article.

Nascent Biotech Announces Orphan Drug Designation for Pancreatic Cancer

Vero Beach, April 25th, 2016 – Nascent Biotech, Inc., (OTC.NBIO) is pleased to announce that it has been granted Orphan Drug Designation from the Office of Orphan Products Development of the FDA for its Pritumumab product for the treatment of Pancreatic cancer. According to Industry statistics, there are approximately 49,000 new cases of Pancreatic Cancer in the United States, annually, with a five year survival rate of 7% and few viable treatment options. This is the second Orphan Drug Designation Granted to Nascent Biotech from the FDA, the first being for use in Primary Brain Cancer.

Dr. Mark Glassy, Nascent Biotech’s founder and Advisory Board Chairman stated, “”It is very satisfying that the FDA has acknowledged the power and importance of Pritumumab in its broad effectiveness in cancer, especially in the un-met need of pancreatic cancer.” He further stated that “We hope to continue to identify additional Orphan Drug Cancers for which Pritumumab will have a significant therapeutic benefit.”

 

About Nascent Biotech, Inc.:

Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.

Safe Harbor:

Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact Information:

 

Nascent Biotech, Inc.

Sean Carrick

President | CEO

601 21st Street Suite 300
Vero Beach, FL 32960

772.713.0541

sean.carrick@nascentbiotech.com

www.nascentbiotech.com

Nascent Biotech Achieves Two Key Milestones in Development of its Novel Brain Cancer Treatment

San Diego, CA August 13, 2015 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO).

Since March of 2014 Nascent has raised $2.1 million which has been used to advance the development of their core product, Pritumumab, to support the filing of an Investigational New Drug exemption (IND). Pritumumab is a fully human monoclonal antibody being developed initially for the treatment of malignant and non malignant Gliomas.

One of the biggest challenges in the development of any antibody product is to show that it can be manufactured, at appropriate scale, to clinical grade and in sufficient quantity for human trials. We have attained this goal and manufactured more than enough product to complete our initial Phase 1/Phase 2 human trials on Brain Cancers, with more than adequate amounts left over to initiate trials in other epithelial cancers such as breast, lung, colon and pancreas. Pritumumab is unique in its ability to react strongly with all these major malignancies.

An additional challenge is to understand the toxicity profile. We have completed a toxicology study, in compliance with FDA guidance, and we have demonstrated no in life toxicities in the two species studied (Monkey and Rat).

Another significant milestone worth noting is that the FDA granted Nascent Biotech an Orphan Drug Designation for Gliomas (brain cancer). “This will give us market exclusivity for a period of 7 years after the drug is approved,” says Nascent President Sean Carrick.

 

About Nascent Biotech, Inc.:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.


Safe Harbor
:
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on October 28, 2014, and future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact Information:

Nascent Biotech, Inc.

Sean Carrick

President

772.713.0541

sean.carrick@nascentbiotech.com

www.nascentbiotech.com

Nascent Biotech, Inc. Announces 2 Additions to Scientific Advisory Board

San Diego, CA June 17, 2014 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announces announced that it has added two internationally renowned cancer experts to its scientific advisory board:

Dr. Santosh Kesari is the director of the Neuro-Oncology Program, director of the Neurotoxicity Treatment Center, director of the Translational Neuro-Oncology Laboratories at Moores Cancer Center and a Professor of Neurosciences at the University Of California San Diego School Of Medicine. Dr. Kesari will be the Principal Clinical Investigator in charge of the Phase I/II human clinical trials in brain cancer for its lead therapeutic monoclonal antibody product Pritumumab.

Dr. Eric F. Glassy is Board certified in Anatomic and Clinical Pathology with a specific interest in Hematopathology, Information Pathology and Digital Pathology as well as being the Medical Director at Pathology Inc. Dr. Glassy is a world recognized Pathologist who has served in several leadership positions in the College of American Pathologists and is a past board member of the CAP Foundation. Dr. Eric Glassy has also authored several publications in his fields of interest and has written and edited key textbooks in the field of pathology. Dr. Eric Glassy’s immunohistology work has confirmed and extended the specificity and comparability of the Pritumumab database.

Nascent Biotech’s Senior Management Team is honored to have Dr. Santosh Kesari and Dr. Eric Glassy as part of their Advisory board.

About Nascent Biotech, Inc.:

Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.

Safe Harbor:

Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on October 28, 2014, and future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact Information:

Nascent Biotech, Inc.
Sean Carrick
President

772.713.0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com

2015 Human Antibodies & Hybridomas Conference

Nascent Biotech will be a key sponsor of the 2015 edition of the Human Antibodies & Hybridomas Conference, held October 28-30, 2015, at the University of Lausanne/CHUV, in Lausanne, Switzerland.

Nascent Biotech CEO Mark Glassy will serve as the program chairman of the Scientific Advisory Committee.

The conference scope will include:

Infectious Diseases · Autoimmunity · Molecular Biology · Emerging Technologies · Clinical Applications · Therapeutic Antibodies · Cancer · Anti-Infective Antibodies · Intellectual Property & Legal Issues

New special session devoted to:
‘ALS and Antibodies’

Click here to download the conference flyer.

Click here to download the conference registration form.

Nascent team members author “Oligoclonal and Polyclonal Antibody Preparations” paper

Nascent founder and chief executive officer Dr. Mark C. Glassy and chief science officer Dr. Rishab K. Gupta authored a new paper published in the Handbook of Therapeutic Antibodies, Second Edition, edited by Stefan Dübel and Janice M. Reichert (Wiley-VCH).

Gupta, R. and Glassy, M. Oligoclonal and Polyclonal Antibody Preparations; in: Handbook of Therapeutic Antibodies; ed by S. Dubel and J. Reichert; 2nd ed.; pgs 1289-1307 (Wiley, 2014).

Please click here to review the paper.

Nascent Team Members Contribute to “Human Monoclonal Antibodies” (Humana Press)

Nascent founder and chief executive officer Dr. Mark C. Glassy and chief science officer Dr. Rishab K. Gupta have contributed a chapter to Humana Press’ new book “Human Monoclonal Antibodies: Methods and Protocols,” edited by Michael Steinitz.

Glassy, M and Gupta, R. Technical and Ethical Limitations in Making Human Monoclonal Antibodies (an overview).  In: Human Monoclonal Antibodies. Methods and Protocols; ed by M. Steinitz; pgs 9-36 (Humana Press, 2013)

To review this chapter, please click here.

American Cancer Society 2014 Cancer Facts and Figures

Please click to download the 2014 Cancer Facts and Figures PDF released by the American Cancer Society.

In addition, please review this document, entitled “Cancer Statistics, 2011; The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths” in PDF format.

Use of the GPEx® System to Increase Production of Pritumumab in a CHO Cell Line

The Journal of Bioprocess Technology has published a paper co-authored by Nascent Biologics Inc. co-founder and chief executive officer Dr. Mark C. Glassy, PhD, entitled “Use of the GPEx® System to Increase Production of Pritumumab in a CHO Cell Line.” This study highlights NBI’s relationship with Catalent, detailed here.

From the paper’s abstract:

Expression of many therapeutic antibodies is not always cost effective due to low level of secretion per cell per day; thus, goal of the present investigations was to determine if the GPEx® technology developed by the Catalent Pharma Solutions could overcome this limitation for the pritumumab. Pritumumab is a natural human IgG1 kappa antibody isolated from a lymph node of a patient with cervical carcinoma. The original human-human hybridoma secreted approximately 1 picogram of antibody per cell per day (pcd). To circumvent this limitation, and to make the antibody more commercially viable, a pritumumab-secreting Chinese Hamster Ovary (CHO) cell line was created using the GPEx® technology. A number of the resulting clones secreted greater than 40 pcd – at least a 40-fold increase over the original human-human hybridoma. Comparison of immunoreactivity of pritumumab produced by the two methods by flow cytometry binding and immunohistochemical staining of tumor tissues revealed them to be comparable. In conclusion, it is clear that application of the GPEx® technology for high level of therapeutic antibody (pritumumab) represents a significant advancement towards its production in a cost effective manner, and circumvents the limitation of low rate of expression for application in therapy and diagnosis of cancer.

Click here to download the complete paper in PDF format.